人α-突触核蛋白表位核酸疫苗pVAX1-IL-4/SYN-B的构建与表达
|
摘要
目的:对本实验小组早期构建的表达人α-突触核蛋白(humanα-synuclein,hα-syn)的核酸疫苗进行优化。设计并构建表达由人白介素4(human IL-4,hIL-4)和人α-突触核蛋白的多个B细胞表位所组成的融合蛋白的真核表达质粒,并检测所构建核酸疫苗的正确性,研究其在哺乳动物COS-7细胞内的表达。
方法:选取hα-syn蛋白的三段B细胞表位基因,其间以两个赖氨酸连接,将设计出的基因序列送往公司合成;采用RT-PCR方法从人类淋巴细胞中扩增hIL-4基因后,通过基因重组技术将其与上述合成的基因序列融合,并在两者之间引入柔性短肽(GSGGGSG);随后将融合基因产物克隆到真核表达载体pVAX1上。然后将重组质粒转化到大肠杆菌DH5α内,抽提质粒,进行限制性内切酶酶切分析和DNA测序鉴定融合质粒的大小、方向和序列。检测合格后采用脂质体转染法,将融合质粒转入COS-7细胞中,用Western blot技术检测其表达情况。
结果:成功扩增了hIL-4基因,并将其与hα-syn的三段B细胞表位基因融合,并克隆到真核表达载体pVAX1上,经限制性内切酶酶切分析和DNA测序,表明重组质粒大小、方向和序列完全正确,成功构建了重组质粒pVAX1-IL-4/SYN-B,以此作为核酸疫苗。经转染哺乳动物COS-7细胞株,并在COS-7中得到有效表达,通过Western blot检测具有较好的生物学活性。
结论:成功构建核酸疫苗pVAX1-IL-4 /SYN-B,并在哺乳动物COS-7细胞中有效表达。所构建的核酸疫苗具有较好的生物学活性,为研究优化后的核酸疫苗在帕金森病动物模型中的免疫治疗的防治效果奠定了基础。
Objective: To construct eukaryotic expression plasmid carryed human IL-4 gene and the B cell epitopes gene ofα-synuclein protein ,and investigate the expression of the plasmid in COS-7 cells. Methods :
The gene of human IL-4 was obtained by RT-PCR and then was fused with the B cell epitopes gene ofα-synuclein protein. A short flexibility peptide was inserted(GSGGGSG)between the gene of human IL-4 and B cell epitomes. The fusional product was cloned into an eukaryotic expression plasmid pVAX1.Then the fusional plasmid was confirmed by electrophoresis and DNA sequencing. The fusional plasmid was transfected into COS-7 cells by liposome transfecting technique,and then identified by Western blotting.
Results : The fusional plasmid,named pVAX1-IL-4 /SYN–B,was constructed and confirmed by DNA sequencing.Meanwhile,the protein extracting in COS-7 cells transfected with the plasmid was showed reactivity with antibody againstα-synuclein.
Conclusion :The pVAX1-IL-4 /SYN–B was constructed successfully and highly expressed in COS-7 cells ,which lay a foundation for further studies.
方法:选取hα-syn蛋白的三段B细胞表位基因,其间以两个赖氨酸连接,将设计出的基因序列送往公司合成;采用RT-PCR方法从人类淋巴细胞中扩增hIL-4基因后,通过基因重组技术将其与上述合成的基因序列融合,并在两者之间引入柔性短肽(GSGGGSG);随后将融合基因产物克隆到真核表达载体pVAX1上。然后将重组质粒转化到大肠杆菌DH5α内,抽提质粒,进行限制性内切酶酶切分析和DNA测序鉴定融合质粒的大小、方向和序列。检测合格后采用脂质体转染法,将融合质粒转入COS-7细胞中,用Western blot技术检测其表达情况。
结果:成功扩增了hIL-4基因,并将其与hα-syn的三段B细胞表位基因融合,并克隆到真核表达载体pVAX1上,经限制性内切酶酶切分析和DNA测序,表明重组质粒大小、方向和序列完全正确,成功构建了重组质粒pVAX1-IL-4/SYN-B,以此作为核酸疫苗。经转染哺乳动物COS-7细胞株,并在COS-7中得到有效表达,通过Western blot检测具有较好的生物学活性。
结论:成功构建核酸疫苗pVAX1-IL-4 /SYN-B,并在哺乳动物COS-7细胞中有效表达。所构建的核酸疫苗具有较好的生物学活性,为研究优化后的核酸疫苗在帕金森病动物模型中的免疫治疗的防治效果奠定了基础。
Objective: To construct eukaryotic expression plasmid carryed human IL-4 gene and the B cell epitopes gene ofα-synuclein protein ,and investigate the expression of the plasmid in COS-7 cells. Methods :
The gene of human IL-4 was obtained by RT-PCR and then was fused with the B cell epitopes gene ofα-synuclein protein. A short flexibility peptide was inserted(GSGGGSG)between the gene of human IL-4 and B cell epitomes. The fusional product was cloned into an eukaryotic expression plasmid pVAX1.Then the fusional plasmid was confirmed by electrophoresis and DNA sequencing. The fusional plasmid was transfected into COS-7 cells by liposome transfecting technique,and then identified by Western blotting.
Results : The fusional plasmid,named pVAX1-IL-4 /SYN–B,was constructed and confirmed by DNA sequencing.Meanwhile,the protein extracting in COS-7 cells transfected with the plasmid was showed reactivity with antibody againstα-synuclein.
Conclusion :The pVAX1-IL-4 /SYN–B was constructed successfully and highly expressed in COS-7 cells ,which lay a foundation for further studies.
引文
[1] Baba M, Nakajo S, Tu PH, Tomita T, et al.Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies[J]. Am J Pathol, 1998 ;152(4):879-84.
[2] Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders[J]. Science. 2000;287:1265–9.
[3] Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease[J].Trends Neurosci. 2000 ;23(10 Suppl):S2-7.
[4] Luthi-Carter R. Progress towards a vaccine for Huntington's disease[J].Mol Ther. 2003;7(5 Pt 1):569-70.
[5] Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature.1999;400: 173–7.
[6] Kawahara K, Hashimoto M, Bar-On P,et al.alpha-Synuclein aggregates interfere with Parkin solubility and distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE[J].J Biol Chem. 2008;283(11): 6979-87.
[7] Setsuie R, Wang YL, Mochizuki H, et al. Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant[J]. Neurochem Int. 2007;50(1):119-29.
[8] Ostrerova N, Petrucelli L, Farrer M, et al.alpha-Synuclein shares physical and functional homology with 14-3-3 proteins[J].J Neurosci. 1999 ;19(14):5782-91.
[9] Lee HJ, Khoshaghideh F, Patel S, et al. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway[J].J Neurosci. 2004 ;24(8): 1888-96.
[10] Bennett MC, Bishop JF, Leng Y, et al. Degradation of alpha-synuclein by proteasome[J].J Biol Chem. 1999 ;274(48):33855-8.
[11] Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunizationprotects dopaminergic neurons in a mouse model of Parkinson's disease[J].Proc Natl Acad Sci USA. 2004;101(25):9435-9440.
[12] Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease[J]. Neuron, 2005; 46(6):857-868.
[13] Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and Pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease[J]. Brain Pathol, 2004; 14:11-20.
[14] Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology[J]. 2005;64: 1553–62.
[15] Rohlff C. Proteomics in molecular medicine: application in central nervous systems disorders [J]. Electropherisis. 2000, 21(6) : 1227-34
[16] Brooks DG, Lee AM, Elsaesser H,et al. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection[J]. J Exp Med. 2008;205(3):533-41.
[17] Chen YX, Wang LX, Tang LF, et al. Boost effect of recombinant IL-4 on protection of Schistosoma japonicum cathepsin B DNA vaccine in mice against the parasite[J].Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2005;23(2):65-8.
[18] Jiang W, Jin N, Cui S, et al. Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector[J].J Virol Methods. 2006 ;136(1-2): 1-7.
[19] Bolesta E, Kowalczyk A, Wierzbicki A,et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery[J].J Immunol. 2006;177(1):177-91.
[20] Miller TW,Shirley TL,Wolfgang WJ,et al.DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype.Mol Ther,2003;7(5 Pt1) :572-579.
[21]张革,邹俊涛,汪华侨等.Aβ42重组多价DNA疫苗的构建及诱导Aβ抗体的产生.第四军医大学学报,2005; 26(10) :865-868.
[22] Kumar M, Behera AK, Hu J,et al. IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy[J]. J Allergy Clin Immunol. 2001; 108(3):402-8.
[23] Ahlers JD, Dunlop N, Alling DW, et al.Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte- macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes[J].J Immunol.1997;158(8): 3947-58.
[24] Fenton RG, Steis RG, Madara K, et al. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma[J].J Immunother Emphasis Tumor Immunol. 1996 ;19(5):364-74.
[25] Kim JJ, Yang JS, Montaner L, et al.Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo[J].J Interferon Cytokine Res. 2000;20(3):311-9.
[26] Wakabayashi K, Tanji K, Mori F,et al.The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates[J].Neuropathology. 2007;27(5):494-506.
[27] Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases[J].Trends Cell Biol. 2004 ;14(12):703-11.
[28] Buneeva OA, Medvedev AE. Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease[J].Biochemistry (Mosc). 2006 ;71(8):851-60.
[29] Berg D, Riess O, Bornemann A. Specification of 14-3-3 proteins in Lewy bodies[J].Ann Neurol. 2003 Jul;54(1):135.
[30] Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease[J].Ann Neurol. 2000 ;47(4):521-3.
[31] Goedert M, Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001, 2(7):492-501.
[32] Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity,neurodegeneration and disease. Trends Neurosci. 1998, 21(6):249-54.
[33] Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1993, 90(23):11282-6.
[34] Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345(1):27-32.
[35] Lee CH, Kim HJ, Lee JH, et al. Dequalinium-induced protofibril formation of alpha-synuclein. J Biol Chem. 2006, 281(6):3463-72.
[36] Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003, 26:267-98.
[37] Serpell LC,Berriman J, Jakes R, et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA. 2000, 97(9):4897-902.
[38] Chen M, Margittai M, Chen J, et al. Investigation of alpha-synuclein fibril structure by site-directed spin labeling. J Biol Chem. 2007, 282(34):24970-9.
[39]王彤钢.白细胞介素4生物学功能研究进展.国外医学免疫学分册,[J]1994, 1:13-17.
[40]何维,孙汶生.医学免疫学[M],北京:人民卫生出版社,2005.280.
[1] Zhang ZX , Roman GC, Hong Z, et a1. Parkinson’S disease in China: prevalence in Beijing, Xi’an, and Shanghai. Lancet 2005; 365(9459): 595-597.
[2] Parkinson J. An essay on the shaking palsy[J]. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223–36.
[3] Elbaz A, Tranchant C.Epidemiologic studies of environmental exposures in Parkinson's disease[J].J Neurol Sci. 2007 ;262(1-2):37-44.
[4] Toda T.Molecular genetics of Parkinson's disease[J].Brain Nerve.2007;59(8): 815-23.
[5] Karakaya S, Kipp M, Beyer C.Oestrogen regulates the expression and function of dopamine transporters in astrocytes of the nigrostriatal system[J].J Neuroendocrinol. 2007 ;19(9):682-90.
[6] Rocca WA, Bower JH, Maraganore DM,et al.Increased risk of parkinsonism in women who underwent oophorectomy before menopause[J].Neurology. 2008 15;70(3):200-9.
[7] de Lau LM, Koudstaal PJ, Witteman JC,et al. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease[J].Neurology. 2006;67(2):315-8.
[8] Powers KM, Smith-Weller T, Franklin GM,et al. Dietary fats, cholesterol and iron as risk factors for Parkinson's disease[DB].Parkinsonism Relat Disord. 2008 Apr 17.
[9] Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson's disease[J].Mov Disord. 2008;23(1):69-74.
[10]陈彪,刘焯霖,王枫.中国帕金森病遗传研究进展[J].中华神经科杂志,2005, 38(3): 160-164.
[11] Bychkov E, Ahmed MR, Dalby KN, et a1. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum [J]. J Neurochem. 2007, 102(3): 699-711.
[12]刘长青,杨正明.侧脑室微量注射左旋多巴治疗大鼠帕金森病.中国临床神经外科杂志,2008, 13(5): 285-287.
[13] Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease[J].Trends Neurosci. 2000 ;23(10 Suppl):S2-7.
[14] Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology, 2004, 62: S56-S63.
[15] Teismann P, Schulz JB. Celluar pathology of Parkinson’s disease: astrocytes, microglia and inflammation[J]. Cell Tissue Res, 2004, 3l8:l49-16l.
[16] Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brain of Parkinson patients treated with 1-deprenyl[J]. J Neurochem, l986, 46: l359-l365.
[17] Le Witt PA. Clinical trials of neuroprotection for Parkinsson’s disease [J]. Neurology, 2004, 63: 23-3l.
[18]张克忠,蒋雨平.单胺氧化酶B抑制剂在治疗帕金森病中的研究.中国临床神经科学,2008, 16(2): l79-l82.
[19] Larumbe Ilundain R, Ferrer Valls JV, Vines Rurda JJ, et al. Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson’s disease [J].Rev Esp Salud Public 2001,75:43-53.
[20] Exter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental lewy body disease [J]. Ann Neurol,1994,35:38-44.
[21]罗蔚锋,包仕尧,刘春风.还原型谷胱甘肽治疗帕金森病的临床研究.中国临床神经科学,2003,11(2): 195-197.
[22] Sechi G, Deledda MG, Boa G, et al .Reduced intravenous glutathione in the treatment of Parkinson’s disease [J]. Prog Neuropsychopharmacol Biol Psychiatry ,1996, 20: 1159-1170.
[23] Meister A, Tate SS, Glutathione and related gamma-glutamyl compoinds [J]. Ann Rev Biochem, 1976,45:559-604.
[24] Tooyama I, Kawamata T, Walker D, et al .Loss of basic fibroblast growth factor in substantia nigra neurons in parkinson’s disease [J].Neurology, 1993, 43: 372-376.
[25] Janaky R, Ogita K, Pasqualotto BA, et al. Glutathione and transduction in the mammalian CNS[J].J Neurochen, 1999,73:889-902.
[26]裴正斌,彭国光.神经营养因子与帕金森病[J].国外医学·内科学分册,2004, 31(6): 252-255.
[27] Katzenschlager R, Evans A, M anson A, et a1. Mucuna pruriens in Parkinson’S disease:a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004; 75(12): 1672-1677.
[28] M anyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiParkinson drug Mucuna pruriens. Phytother Res 2004; 18: 706-712.
[29]张琳,刘树民.刺五加防治帕金森病研究进展.中国中医药信息杂志.2007, 14(3): 95-96.
[30]赵虹,李文伟,高俊鹏等.补肾养肝方药治疗肝肾阴虚型帕金森病临床研究.中国中西医结合杂志,2007, 27(9): 780-784.
[31]胡玉英.综合疗法治疗帕金森病的临床研究.辽宁中医杂志,2008, 35(1): 65-67.
[32]沈涌,罗烈岚.通心络胶囊、六味地黄丸与美多巴合用治疗帕金森病.浙江中医药大学学报,2008, 32(2): 197-198.
[33]戚秀杰,王顺.针灸治疗帕金森病临床研究进展.针灸临床杂志.2007, 23 (7):68-69.
[34]姜雪梅,黄泳一,卓鹰等.头电针治疗帕金森病的疗效观察.南方医科大学学报,2006, 26(1): 114-116.
[35]孙伯民.帕金森病的手术治疗.老年医学与保健,2006, 12(4): 208-211.
[36]陈焕林,邵立民,邵永良等.微电极导向脑内核团毁损术治疗帕金森病.立体定向和功能性神经外科杂志,2006, 19(1): 49-50.
[37] Alterman RL, Sterio D, Beric A, et a1. Microdeetrode recording during posteroventral pallidotomy: impact on target selection and complications [J]. Neurosurg, 1999, 44: 315-319.
[38]李勇杰.运动障碍病1135例手术治疗报告[J].中华神经外科杂志.2001, 11(7): 350-353.
[39] Benaid AL, Pollak P, Louveau A, et a1. Combined(thalamotomy and stimulation) stereotactic surgery of the VIM thalamicnucleus for bilateral Parkinson’s disease. Appl Neurophysio1,1987, 50 (1-6): 344-346.
[40] Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders, J Neurosurg, 1996,84(2):203-214.
[41] Limousin P, speelman JD, Gielen F, et a1. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry, l999, 66(3): 289-296.
[42] Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars intema of the globus pallidus in Parkinson’s disease. N Engl J Med, 200l, 345(13): 956-963.
[43] Ogura M, Nakao N, Nakai E, et a1 . The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease. J Neurosurg , 2004, l00 (6): 997-l001.
[44] Benabid AL, Kraek PP, Benazzouz A, et a1. Deep brain stimulation of the subthalamic nucleus for Pakinson’s disease: Methodologic aspects and clinical criteria. Neurology, 2000, 55(12 Suppl 6): S40-S44.
[45] Fraix V, Houeto JL, Lagrange C, et a1. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 2006, 77(4): 443-449.
[46] Capecci M, Ricciuti RA, Burini D, et a1. Functional imprevement after subthalamic stimulation in Parkinson’s disease: a non-equivalent controlled study with l2-24month follow up. J Neurol Neurosurg Psychiatry, 2005, 76(6): 769-774.
[47] Pahwa R, Wilkinson SB, Overman J, et a1. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg, 2003, 99(1): 71-77.
[48] Esselink RA, de Bie RM, de Haan RJ, et a1. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized tria1. Neurology, 2004, 62(2): 20l-207.
[49] Kumar R, Lozano AM, Sime E, et a1. Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. Neurology, 1999, 53 (3): 561-566.
[50] Kleiner-Fisman G , Fisman DN, Sime E, et a1. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg, 2003, 99 (3): 489-495.
[51] Lopez-Lozano JJ, Bravo G, Abascal J, et a1. Clinical outcome of cotransplantatian of peripheral nerve and adrenal medulla in patients with Parkinson’s disease[J]. J Neurosurg, 1999, 90(5): 875-882.
[52] Bjorklund LM, Sanchez O, Pernaute R, et al. Embryonic stem cells devdop into functional dopaminergic neurons after transplantation in a Parkinson rat model [J]. Proc Natl Acad Sci USA, 2002, 99: 2344-2452.
[53] Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells’function in an animal model Parkinson’s disease [J]. Nature, 2002, 418: 50-56.
[54] Takagi Y, Takahashi J, Saiki H, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate nmdel[J]. J Clin Invest. 2005, 115: 102-109.
[55] Li Y, Chen J, Wang L, et a1. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson s disease. Neurosci Lett, 2001, 316(2): 67-70.
[56] Li Y, Chen J, Chen XG, et a1. Human marrow stromal cell therapy for stroke in rat: neuotrophins and functional recovery. Neurology, 2002, 59:514-523.
[57] Chen X, Katakowski M, Li Y, et a1. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production. J Neurosci Res, 2002, 69(5): 687-691.
[58] Wolff JA, Fisher LJ, Xu L, et a1. Grafting fibroblasts genetically modified to produce L-dopainarat model of Parkinson disease. Proc Natl Acad Sci USA 1989: 86(22): 9011-9014.
[59] Monville C,Torres E, Thomas E, et a1. HSV vector-delivery of GDNF in a rat model of PD: partial efficacy obscured by vector toxicity. Brain Res 2004; 1024(1-2): 1-15.
[60] Torresa EM, Monvillea C, Lowensteinb PR, et a1.1n vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. Brain Res Mol Brain Res 2005; 137(1-2): 1-10.
[61] Park S, Kim EY, Ghil GS, et a1. Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson’s disease. Neurosci Lett 2003; 353(2): 91-94.
[62] Corso TD, Torres G, Goulah C, et a1. Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of stnatal dopamine. Brain Res Mol Brain Res 2005; 139(2): 361-366.
[63] Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in Parkinsonism. Neurobiol Dis 2005; 18(1): 19-31.
[64] Sinhaa R, Racetteb B, Perlmutter JS, et a1. Prevalence of parkin gene mutations and vanations in idiopathic Parkinson’s disease. Parkinsonism relat disord 2005; 11(6): 341-347.
[65] Purisai MG, McCormack AL, Langston W J, et a1. Alpha-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 2005; 20(3): 898-906.
[66] Bonin M. Poths S, Osaka H, et a1. Microarray expression analysis of gad mice implicates involvement of Parkinson’s disease associated UCH-L1 in multiple metabolic pathways. Brain Res Mol Brain Res 2004; 126(1): 88-97.
[67] Wakabayashi K, Tanji K, Mori F, et al. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates[J]. Neuropathology. 2007; 27 (5): 494-506.
[68] Shults CW. Lewy bodies. [J]. Proc Natl Acad Sci USA. 2006; 103: 1661–8.
[69] Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. [J].Nature. 1997;388: 839–40.
[70] Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. [J].Proc Natl Acad Sci USA. 2004;101(25):9435-9440.
[71] Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immuniz- ation in a mouse model of Parkinson's disease. [J]. Neuron. 2005;46:857–68.
[2] Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders[J]. Science. 2000;287:1265–9.
[3] Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease[J].Trends Neurosci. 2000 ;23(10 Suppl):S2-7.
[4] Luthi-Carter R. Progress towards a vaccine for Huntington's disease[J].Mol Ther. 2003;7(5 Pt 1):569-70.
[5] Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature.1999;400: 173–7.
[6] Kawahara K, Hashimoto M, Bar-On P,et al.alpha-Synuclein aggregates interfere with Parkin solubility and distribution: ROLE IN THE PATHOGENESIS OF PARKINSON DISEASE[J].J Biol Chem. 2008;283(11): 6979-87.
[7] Setsuie R, Wang YL, Mochizuki H, et al. Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant[J]. Neurochem Int. 2007;50(1):119-29.
[8] Ostrerova N, Petrucelli L, Farrer M, et al.alpha-Synuclein shares physical and functional homology with 14-3-3 proteins[J].J Neurosci. 1999 ;19(14):5782-91.
[9] Lee HJ, Khoshaghideh F, Patel S, et al. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway[J].J Neurosci. 2004 ;24(8): 1888-96.
[10] Bennett MC, Bishop JF, Leng Y, et al. Degradation of alpha-synuclein by proteasome[J].J Biol Chem. 1999 ;274(48):33855-8.
[11] Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunizationprotects dopaminergic neurons in a mouse model of Parkinson's disease[J].Proc Natl Acad Sci USA. 2004;101(25):9435-9440.
[12] Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease[J]. Neuron, 2005; 46(6):857-868.
[13] Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and Pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease[J]. Brain Pathol, 2004; 14:11-20.
[14] Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology[J]. 2005;64: 1553–62.
[15] Rohlff C. Proteomics in molecular medicine: application in central nervous systems disorders [J]. Electropherisis. 2000, 21(6) : 1227-34
[16] Brooks DG, Lee AM, Elsaesser H,et al. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection[J]. J Exp Med. 2008;205(3):533-41.
[17] Chen YX, Wang LX, Tang LF, et al. Boost effect of recombinant IL-4 on protection of Schistosoma japonicum cathepsin B DNA vaccine in mice against the parasite[J].Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2005;23(2):65-8.
[18] Jiang W, Jin N, Cui S, et al. Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector[J].J Virol Methods. 2006 ;136(1-2): 1-7.
[19] Bolesta E, Kowalczyk A, Wierzbicki A,et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery[J].J Immunol. 2006;177(1):177-91.
[20] Miller TW,Shirley TL,Wolfgang WJ,et al.DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype.Mol Ther,2003;7(5 Pt1) :572-579.
[21]张革,邹俊涛,汪华侨等.Aβ42重组多价DNA疫苗的构建及诱导Aβ抗体的产生.第四军医大学学报,2005; 26(10) :865-868.
[22] Kumar M, Behera AK, Hu J,et al. IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy[J]. J Allergy Clin Immunol. 2001; 108(3):402-8.
[23] Ahlers JD, Dunlop N, Alling DW, et al.Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte- macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes[J].J Immunol.1997;158(8): 3947-58.
[24] Fenton RG, Steis RG, Madara K, et al. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma[J].J Immunother Emphasis Tumor Immunol. 1996 ;19(5):364-74.
[25] Kim JJ, Yang JS, Montaner L, et al.Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo[J].J Interferon Cytokine Res. 2000;20(3):311-9.
[26] Wakabayashi K, Tanji K, Mori F,et al.The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates[J].Neuropathology. 2007;27(5):494-506.
[27] Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases[J].Trends Cell Biol. 2004 ;14(12):703-11.
[28] Buneeva OA, Medvedev AE. Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease[J].Biochemistry (Mosc). 2006 ;71(8):851-60.
[29] Berg D, Riess O, Bornemann A. Specification of 14-3-3 proteins in Lewy bodies[J].Ann Neurol. 2003 Jul;54(1):135.
[30] Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease[J].Ann Neurol. 2000 ;47(4):521-3.
[31] Goedert M, Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001, 2(7):492-501.
[32] Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity,neurodegeneration and disease. Trends Neurosci. 1998, 21(6):249-54.
[33] Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1993, 90(23):11282-6.
[34] Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345(1):27-32.
[35] Lee CH, Kim HJ, Lee JH, et al. Dequalinium-induced protofibril formation of alpha-synuclein. J Biol Chem. 2006, 281(6):3463-72.
[36] Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003, 26:267-98.
[37] Serpell LC,Berriman J, Jakes R, et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA. 2000, 97(9):4897-902.
[38] Chen M, Margittai M, Chen J, et al. Investigation of alpha-synuclein fibril structure by site-directed spin labeling. J Biol Chem. 2007, 282(34):24970-9.
[39]王彤钢.白细胞介素4生物学功能研究进展.国外医学免疫学分册,[J]1994, 1:13-17.
[40]何维,孙汶生.医学免疫学[M],北京:人民卫生出版社,2005.280.
[1] Zhang ZX , Roman GC, Hong Z, et a1. Parkinson’S disease in China: prevalence in Beijing, Xi’an, and Shanghai. Lancet 2005; 365(9459): 595-597.
[2] Parkinson J. An essay on the shaking palsy[J]. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223–36.
[3] Elbaz A, Tranchant C.Epidemiologic studies of environmental exposures in Parkinson's disease[J].J Neurol Sci. 2007 ;262(1-2):37-44.
[4] Toda T.Molecular genetics of Parkinson's disease[J].Brain Nerve.2007;59(8): 815-23.
[5] Karakaya S, Kipp M, Beyer C.Oestrogen regulates the expression and function of dopamine transporters in astrocytes of the nigrostriatal system[J].J Neuroendocrinol. 2007 ;19(9):682-90.
[6] Rocca WA, Bower JH, Maraganore DM,et al.Increased risk of parkinsonism in women who underwent oophorectomy before menopause[J].Neurology. 2008 15;70(3):200-9.
[7] de Lau LM, Koudstaal PJ, Witteman JC,et al. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease[J].Neurology. 2006;67(2):315-8.
[8] Powers KM, Smith-Weller T, Franklin GM,et al. Dietary fats, cholesterol and iron as risk factors for Parkinson's disease[DB].Parkinsonism Relat Disord. 2008 Apr 17.
[9] Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson's disease[J].Mov Disord. 2008;23(1):69-74.
[10]陈彪,刘焯霖,王枫.中国帕金森病遗传研究进展[J].中华神经科杂志,2005, 38(3): 160-164.
[11] Bychkov E, Ahmed MR, Dalby KN, et a1. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum [J]. J Neurochem. 2007, 102(3): 699-711.
[12]刘长青,杨正明.侧脑室微量注射左旋多巴治疗大鼠帕金森病.中国临床神经外科杂志,2008, 13(5): 285-287.
[13] Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease[J].Trends Neurosci. 2000 ;23(10 Suppl):S2-7.
[14] Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology, 2004, 62: S56-S63.
[15] Teismann P, Schulz JB. Celluar pathology of Parkinson’s disease: astrocytes, microglia and inflammation[J]. Cell Tissue Res, 2004, 3l8:l49-16l.
[16] Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brain of Parkinson patients treated with 1-deprenyl[J]. J Neurochem, l986, 46: l359-l365.
[17] Le Witt PA. Clinical trials of neuroprotection for Parkinsson’s disease [J]. Neurology, 2004, 63: 23-3l.
[18]张克忠,蒋雨平.单胺氧化酶B抑制剂在治疗帕金森病中的研究.中国临床神经科学,2008, 16(2): l79-l82.
[19] Larumbe Ilundain R, Ferrer Valls JV, Vines Rurda JJ, et al. Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson’s disease [J].Rev Esp Salud Public 2001,75:43-53.
[20] Exter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental lewy body disease [J]. Ann Neurol,1994,35:38-44.
[21]罗蔚锋,包仕尧,刘春风.还原型谷胱甘肽治疗帕金森病的临床研究.中国临床神经科学,2003,11(2): 195-197.
[22] Sechi G, Deledda MG, Boa G, et al .Reduced intravenous glutathione in the treatment of Parkinson’s disease [J]. Prog Neuropsychopharmacol Biol Psychiatry ,1996, 20: 1159-1170.
[23] Meister A, Tate SS, Glutathione and related gamma-glutamyl compoinds [J]. Ann Rev Biochem, 1976,45:559-604.
[24] Tooyama I, Kawamata T, Walker D, et al .Loss of basic fibroblast growth factor in substantia nigra neurons in parkinson’s disease [J].Neurology, 1993, 43: 372-376.
[25] Janaky R, Ogita K, Pasqualotto BA, et al. Glutathione and transduction in the mammalian CNS[J].J Neurochen, 1999,73:889-902.
[26]裴正斌,彭国光.神经营养因子与帕金森病[J].国外医学·内科学分册,2004, 31(6): 252-255.
[27] Katzenschlager R, Evans A, M anson A, et a1. Mucuna pruriens in Parkinson’S disease:a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004; 75(12): 1672-1677.
[28] M anyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiParkinson drug Mucuna pruriens. Phytother Res 2004; 18: 706-712.
[29]张琳,刘树民.刺五加防治帕金森病研究进展.中国中医药信息杂志.2007, 14(3): 95-96.
[30]赵虹,李文伟,高俊鹏等.补肾养肝方药治疗肝肾阴虚型帕金森病临床研究.中国中西医结合杂志,2007, 27(9): 780-784.
[31]胡玉英.综合疗法治疗帕金森病的临床研究.辽宁中医杂志,2008, 35(1): 65-67.
[32]沈涌,罗烈岚.通心络胶囊、六味地黄丸与美多巴合用治疗帕金森病.浙江中医药大学学报,2008, 32(2): 197-198.
[33]戚秀杰,王顺.针灸治疗帕金森病临床研究进展.针灸临床杂志.2007, 23 (7):68-69.
[34]姜雪梅,黄泳一,卓鹰等.头电针治疗帕金森病的疗效观察.南方医科大学学报,2006, 26(1): 114-116.
[35]孙伯民.帕金森病的手术治疗.老年医学与保健,2006, 12(4): 208-211.
[36]陈焕林,邵立民,邵永良等.微电极导向脑内核团毁损术治疗帕金森病.立体定向和功能性神经外科杂志,2006, 19(1): 49-50.
[37] Alterman RL, Sterio D, Beric A, et a1. Microdeetrode recording during posteroventral pallidotomy: impact on target selection and complications [J]. Neurosurg, 1999, 44: 315-319.
[38]李勇杰.运动障碍病1135例手术治疗报告[J].中华神经外科杂志.2001, 11(7): 350-353.
[39] Benaid AL, Pollak P, Louveau A, et a1. Combined(thalamotomy and stimulation) stereotactic surgery of the VIM thalamicnucleus for bilateral Parkinson’s disease. Appl Neurophysio1,1987, 50 (1-6): 344-346.
[40] Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders, J Neurosurg, 1996,84(2):203-214.
[41] Limousin P, speelman JD, Gielen F, et a1. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry, l999, 66(3): 289-296.
[42] Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars intema of the globus pallidus in Parkinson’s disease. N Engl J Med, 200l, 345(13): 956-963.
[43] Ogura M, Nakao N, Nakai E, et a1 . The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease. J Neurosurg , 2004, l00 (6): 997-l001.
[44] Benabid AL, Kraek PP, Benazzouz A, et a1. Deep brain stimulation of the subthalamic nucleus for Pakinson’s disease: Methodologic aspects and clinical criteria. Neurology, 2000, 55(12 Suppl 6): S40-S44.
[45] Fraix V, Houeto JL, Lagrange C, et a1. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatry, 2006, 77(4): 443-449.
[46] Capecci M, Ricciuti RA, Burini D, et a1. Functional imprevement after subthalamic stimulation in Parkinson’s disease: a non-equivalent controlled study with l2-24month follow up. J Neurol Neurosurg Psychiatry, 2005, 76(6): 769-774.
[47] Pahwa R, Wilkinson SB, Overman J, et a1. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg, 2003, 99(1): 71-77.
[48] Esselink RA, de Bie RM, de Haan RJ, et a1. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized tria1. Neurology, 2004, 62(2): 20l-207.
[49] Kumar R, Lozano AM, Sime E, et a1. Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. Neurology, 1999, 53 (3): 561-566.
[50] Kleiner-Fisman G , Fisman DN, Sime E, et a1. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg, 2003, 99 (3): 489-495.
[51] Lopez-Lozano JJ, Bravo G, Abascal J, et a1. Clinical outcome of cotransplantatian of peripheral nerve and adrenal medulla in patients with Parkinson’s disease[J]. J Neurosurg, 1999, 90(5): 875-882.
[52] Bjorklund LM, Sanchez O, Pernaute R, et al. Embryonic stem cells devdop into functional dopaminergic neurons after transplantation in a Parkinson rat model [J]. Proc Natl Acad Sci USA, 2002, 99: 2344-2452.
[53] Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells’function in an animal model Parkinson’s disease [J]. Nature, 2002, 418: 50-56.
[54] Takagi Y, Takahashi J, Saiki H, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate nmdel[J]. J Clin Invest. 2005, 115: 102-109.
[55] Li Y, Chen J, Wang L, et a1. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson s disease. Neurosci Lett, 2001, 316(2): 67-70.
[56] Li Y, Chen J, Chen XG, et a1. Human marrow stromal cell therapy for stroke in rat: neuotrophins and functional recovery. Neurology, 2002, 59:514-523.
[57] Chen X, Katakowski M, Li Y, et a1. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production. J Neurosci Res, 2002, 69(5): 687-691.
[58] Wolff JA, Fisher LJ, Xu L, et a1. Grafting fibroblasts genetically modified to produce L-dopainarat model of Parkinson disease. Proc Natl Acad Sci USA 1989: 86(22): 9011-9014.
[59] Monville C,Torres E, Thomas E, et a1. HSV vector-delivery of GDNF in a rat model of PD: partial efficacy obscured by vector toxicity. Brain Res 2004; 1024(1-2): 1-15.
[60] Torresa EM, Monvillea C, Lowensteinb PR, et a1.1n vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system. Brain Res Mol Brain Res 2005; 137(1-2): 1-10.
[61] Park S, Kim EY, Ghil GS, et a1. Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson’s disease. Neurosci Lett 2003; 353(2): 91-94.
[62] Corso TD, Torres G, Goulah C, et a1. Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of stnatal dopamine. Brain Res Mol Brain Res 2005; 139(2): 361-366.
[63] Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in Parkinsonism. Neurobiol Dis 2005; 18(1): 19-31.
[64] Sinhaa R, Racetteb B, Perlmutter JS, et a1. Prevalence of parkin gene mutations and vanations in idiopathic Parkinson’s disease. Parkinsonism relat disord 2005; 11(6): 341-347.
[65] Purisai MG, McCormack AL, Langston W J, et a1. Alpha-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 2005; 20(3): 898-906.
[66] Bonin M. Poths S, Osaka H, et a1. Microarray expression analysis of gad mice implicates involvement of Parkinson’s disease associated UCH-L1 in multiple metabolic pathways. Brain Res Mol Brain Res 2004; 126(1): 88-97.
[67] Wakabayashi K, Tanji K, Mori F, et al. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates[J]. Neuropathology. 2007; 27 (5): 494-506.
[68] Shults CW. Lewy bodies. [J]. Proc Natl Acad Sci USA. 2006; 103: 1661–8.
[69] Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. [J].Nature. 1997;388: 839–40.
[70] Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. [J].Proc Natl Acad Sci USA. 2004;101(25):9435-9440.
[71] Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immuniz- ation in a mouse model of Parkinson's disease. [J]. Neuron. 2005;46:857–68.